Gilead Sciences Gains Orphan Drug Status For Liver Treatment, Shares Move Higher
January 07, 2015 at 11:27 AM EST
Gilead Sciences, Inc. (NASDAQ: GILD) obtained orphan drug status on Monday for its simtuzumab as a treatment for a rare disorder ...